Development of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid‐Free Analgesics
Angewandte Chemie International Edition · 2024
DOI: 10.1002/anie.202405941 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2024. Verfasst von Michael Desgagné und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke…. Hauptthemen laut MEDLINE: Receptors, Neurotensin, Macrocyclic Compounds. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
The opioid crisis has highlighted the urgent need to develop non‐opioid alternatives for managing pain, with an effective, safe, and non‐addictive pharmacotherapeutic profile. Using an extensive structure–activity relationship approach, here we have identified a new series of highly selective neurotensin receptor type 2 (NTS2) macrocyclic compounds that exert potent, opioid‐independent analgesia in various experimental pain models. To our knowledge, the constrained macrocycle in which the Ile 12 residue of NT(7–12) was substituted by cyclopentylalanine, Pro 7 and Pro 10 were replaced by allyl‐glycine followed by side‐chain to side‐chain cyclization is the most selective analog targeting NTS2 identified to date ( K i 2.9 nM), showing 30,000‐fold selectivity over NTS1. Of particular importance, this macrocyclic analog is also able to potentiate the analgesic effects of morphine in a dose‐ and time‐dependent manner. Exerting complementary analgesic actions via distinct mechanisms of nociceptive transmission, NTS2‐selective macrocycles can therefore be exploited as opioid‐free analgesics or as opioid‐sparing therapeutics, offering superior pain relief with reduced adverse effects to pain patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Avenue Nord, J1H 5N4, Sherbrooke, Québec, Canada.
ORCID-Profile: Michael Desgagné, Sára Ferková, Jean-Michel Longpré, Jérôme Côté, Pierre-Luc Boudreault, Philippe Sarret
Förderung
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Desgagné, M., Chartier, M., Lagard, C., Ferková, S., Choquette, M., Longpré, J. M., Côté, J., Boudreault, P. L., & Sarret, P. (2024). Development of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid‐Free Analgesics. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202405941
Vancouver
Desgagné M, Chartier M, Lagard C, Ferková S, Choquette M, Longpré JM, et al. Development of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid‐Free Analgesics. Angewandte Chemie International Edition. 2024. doi:10.1002/anie.202405941
BibTeX
@article{Desgagn2024,
author = {Desgagné, Michael and Chartier, Magali and Lagard, Camille and Ferková, Sára and Choquette, Mathieu and Longpré, Jean-Michel and Côté, Jérôme and Boudreault, Pierre-Luc and Sarret, Philippe},
title = {Development of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid‐Free Analgesics},
journal = {Angewandte Chemie International Edition},
year = {2024},
doi = {10.1002/anie.202405941}
}
EUVIMED